Verve Therapeutics 2025 Q1 Earnings Beats Expectations, Net Loss Improves 36.3%

Verve Therapeutics (VERV) reported its fiscal 2025 Q1 earnings on May 14th, 2025. The company exceeded Wall Street expectations, posting a loss of $0.35 per share, significantly better than the anticipated $0.71 per share loss. Revenue also topped forecasts at $33 million, compared to the expected $7.1 million. Verve maintains an optimistic outlook, anticipating the dosing of the first patient in the Phase 2 clinical trial of VERVE-102 later this year, aligning with its strategic goals and ongoing clinical trials.

Revenue
Verve Therapeutics experienced a remarkable increase in total revenue, reaching $32.98 million in 2025 Q1, compared to $5.70 million in 2024 Q1, representing a 479.0% growth. This revenue growth was driven entirely by collaboration revenue, which accounted for the entire $32.98 million.

Earnings/Net Income
Verve Therapeutics reduced its net loss to $31.03 million in 2025 Q1, showing a 36.3% improvement from the $48.74 million loss in 2024 Q1. The loss per share narrowed from $0.59 to $0.35, signifying progress despite ongoing financial challenges.

Post-Earnings Price Action Review
Following Verve Therapeutics' impressive revenue beat and earnings surprise, a strategy of buying VERV shares and holding for 30 days is suggested due to potential short-term gains. The company's revenue exceeded analyst estimates by 36% for 2024, and EPS also surpassed expectations by 6%. This positive momentum may attract investor interest, potentially leading to further price appreciation. Although the biotech industry is inherently volatile, VERV's clinical trial progress and strong cash position provide a promising outlook. Backtesting similar strategies has shown effectiveness with holding periods of 1 to 30 days, aligning with the proposed 30-day timeframe. However, investors should consider the market's volatility and VERV-specific developments when determining the optimal holding period.

CEO Commentary
Verve Therapeutics is experiencing a robust start to 2025, marked by significant clinical and regulatory advancements. Dr. Sekar Kathiresan, M.D., co-founder and CEO, highlighted promising initial data from the Heart-2 clinical trial of VERVE-102, indicating well-tolerated treatment leading to substantial, dose-dependent reductions in LDL-C levels. He noted that VERVE-102 has the potential to shift treatment paradigms in cardiovascular care from chronic to a single-dose solution. Dr. Kathiresan expressed confidence in the company’s position, emphasizing a cash runway into mid-2027, which supports their strategic goals and ongoing clinical trials.

Guidance
The company anticipates dosing the first patient in the Phase 2 clinical trial of VERVE-102 in the second half of 2025. Further updates are expected later in 2025, including final data from the Heart-2 trial's dose escalation phase, delivery of the opt-in package, and a decision from Eli Lilly regarding the PCSK9 program. Verve also expects to provide an update on the VERVE-201 program targeting ANGPTL3, reinforcing its commitment to advancing its clinical pipeline and addressing unmet needs in cardiovascular disease treatment.

Additional News
Verve Therapeutics has been actively advancing its pipeline, having received a Fast Track designation from the U.S. FDA for its VERVE-102 program, aimed at treating hyperlipidemia and reducing LDL-C levels. This designation facilitates the development and expedites the review process of the drug. Additionally, Verve announced positive initial data from its Heart-2 Phase 1b clinical trial of VERVE-102, demonstrating significant reductions in LDL-C levels among participants. The company is well-positioned financially, with a cash runway extending into mid-2027, supporting its ongoing clinical trials and regulatory goals. These developments reflect Verve's strategic focus on delivering innovative genetic medicines in the cardiovascular space.